Modality
Nanobody
MOA
BiTE
Target
USP1
Pathway
PI3K/AKT
Gastric CaAngelmanNB
Development Pipeline
Preclinical
Jul 2023
→ Dec 2025
PreclinicalCurrent
NCT07969268
49 pts·NB
2023-07→2025-12·Recruiting
49 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-183mo agoInterim· NB
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Recruit…
Catalysts
Interim
2025-12-18 · 3mo ago
NB
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07969268 | Preclinical | NB | Recruiting | 49 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| SND-5878 | Syndax | NDA/BLA | Menin | |
| Tezesotorasib | Enliven | Phase 2 | USP1 |